Pancreatic Cancer Research

ResearcherAlbert Einstein College of MedicineActive in the last 2 years

John Christopher McAuliffe

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5020574581, A5135448216; NIH RePORTER profile ID 9442423. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
2
Labs led
1
Collaborators
32
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 2 papers · 2026: 2 papers, 2 grants

Papers 8

  1. Tie2 inhibition disrupts TMEM doorway function and reduces dissemination in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-026-03730-6↗
  2. Mena (ENAH) Promotes KRAS-Driven Tumor Growth and Metastatic Progression in Pancreatic Ductal Adenocarcinoma Last author DOI 10.64898/2026.01.07.698161↗
  3. Hepatitis C Virus Infection and Pancreatic Cancer Risk in US Veterans. Last author DOI 10.1001/jamanetworkopen.2025.43710↗
  4. Intraoperative Margin Analysis Does Not Improve Outcomes in Treatment-Naive or Neoadjuvantly-Treated Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2025.100826↗
  5. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Co-author DOI 10.1126/scitranslmed.abc1600↗
  6. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-20-1826↗
  7. Pancreatic Cancer Surgery Following Emergency Department Admission: Understanding Poor Outcomes and Disparities in Care. Co-author DOI 10.1007/s11605-020-04614-6↗
  8. Type 2 diabetes mellitus and pancreatic cancer. Co-author DOI 10.1016/j.suc.2013.02.003↗

Grants 2

  1. Dormancy and Pancreatic Adenocarcinoma Recurrence R03CA308630↗
  2. Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients R42CA287679↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julio A. Aguirre-Ghiso · 1 shared grant, 2026 · strength 1.26
  2. Claudia Gravekamp · 1 shared paper, 1 shared grant, 2022–2026 · strength 0.97
  3. Chaoyuan Kuang · 1 shared grant, 2026 · strength 0.86
  4. Chris Bradley · 1 shared grant, 2026 · strength 0.86
  5. Nicole C. Panarelli · 3 shared papers, 2025–2026 · strength 0.83
  6. Lina A. Ariyan · 2 shared papers, 2026 · strength 0.51
  7. Érika Pereira Zambalde · 2 shared papers, 2026 · strength 0.51
  8. En Cheng · 1 shared paper, 2025 · strength 0.42
  9. Ben Z. Stanger · 2 shared papers, 2022–2026 · strength 0.34
  10. Xing Li · 1 shared paper, 2025 · strength 0.33
  11. Vishes V. Mehta · 1 shared paper, 2021 · strength 0.17
  12. Peter Muscarella · 1 shared paper, 2021 · strength 0.17
  13. Haejin In · 1 shared paper, 2021 · strength 0.17
  14. Vinod P. Balachandran · 1 shared paper, 2022 · strength 0.11
  15. Dinesh Chandra · 1 shared paper, 2022 · strength 0.11
  16. Benson Chellakkan Selvanesan · 1 shared paper, 2022 · strength 0.11
  17. Jennifer W. Chuy · 1 shared paper, 2022 · strength 0.11
  18. Wilber Quispe‐Tintaya · 1 shared paper, 2022 · strength 0.11
  19. David Balli · 1 shared paper, 2022 · strength 0.10
  20. Robert J. Norgard · 1 shared paper, 2022 · strength 0.10
  21. Pichai Raman · 1 shared paper, 2022 · strength 0.10
  22. Jinyang Li · 1 shared paper, 2022 · strength 0.10
  23. Ravikanth Maddipati · 1 shared paper, 2022 · strength 0.10
  24. Scott W. Lowe · 1 shared paper, 2022 · strength 0.10
  25. Taku Higashihara · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.